Critical Conversations: TIL Webinar Series
HOPA's Collaboration with the Oncology Nursing Society (ONS) Continues with Webinar #2 on TIL Therapy
Filling the Gap in Professional Knowledge Sharing
In mid-February 2024, the Food and Drug Administration approved the world's first ever tumor-infiltrating lymphocyte (TIL) therapy for people with advanced melanoma. Along with its success comes a fast-growing demand for patient access and the development of new TIL therapy sites. Currently, there are gaps in providing TIL therapy. There are also gaps in professional knowledge-sharing.
This collaboration between HOPA and ONS is an effort to demonstrate how two organizations can learn together to better understand the logistics of bringing TIL therapy to patients who might benefit from this treatment.
Three Webinars with Three Insights to TIL Therapy
These webinars will offer "behind the scenes" views to TIL therapy. Each webinar will be curated with different content, presented by HOPA and ONS members who will offer their unique vantage points.
Each webinar is 60 minutes in length.
Register for Webinar #2 here
You may be interested in one webinar, or maybe all of them - it is your choice! Registration is being offered a la carte. Registration will open for Webinar #2 on Tuesday, October 1.
Registration for all three webinars is being offered at no cost.
TIL Webinar #2: Keep Working TIL We Beat Melanoma! The Operations and Science Behind TIL Therapy
Tuesday, October 29 - 1:00-2:00 PM CT, via Zoom
Topic
- Operationalizing TIL Therapy - Science and Side Effects
Learning Objectives
- Explain the mechanism of action of TIL therapy
- Summarize the workflow of treating a patient with TIL therapy
- Compare best practices for safe administration of IL-2
- Identify common barriers to implementing a TILs program
Session Description
Join us for a panel discussion regarding FDA-approved TIL therapy for melanoma. We will discuss the mechanism of action and toxicities of TIL therapy, lymphodepleting (LD) chemo, and IL-2. Additionally, we'll review logistics for scheduling resections, out-of-specification products, best practices for safely administering IL-2, pharmacy logistics for IL-2, and where TILs may be in the future.
There will be 1.0 CE credit and 1.0 NCPD credit available for Webinar #2.
Click here to register for Webinar #2
Meet Our Moderator
Dr. Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Dr. Mahmoudjafari is a Clinical Pharmacy Manager at the University of Kansas Health System in Kansas City, Kansas.
She has presented nationally on her experience with managing high-cost therapies, and on clinical topics such as CAR T-cell therapies, acute and chronic graft versus host disease, and the management of fungal infections in hematopoietic stem cell transplantation.
Her expert knowledge and friendly presentation style makes her an excellent choice to moderate this series!
Meet Our Speakers
Patricia Chambers, BSN, RN, BMTCN
Patricia Chambers is a Nurse Educator at Moffitt Cancer Center in Tampa, FL with experience working with commercial and investigational products in the Cellular Immunotherapy unit.
Dr. Jennifer Collins, PharmD, BCOP
Dr. Collins practices as an Oncology Clinical Pharmacy Specialist in Cellular Therapy and Hematology at UChicago Medicine (NCI-designated and ranked as a Top 50 institute per U.S. News & World Report).
Andrea Fadel, BSN, RN, OCN, BMTCN
Andrea Fadel is a Transplant and Cellular Therapy Nurse Coordinator at University of Chicago Medicine.
Dr. Amanda Pawlenty, PharmD, BCOP
Dr. Pawlenty is the Senior Clinical Manager for the inpatient Hematology/Oncology/BMT pharmacy practice at Mayo Clinic in Rochester, Minnesota.
Follow this link to register
Stay tuned for Webinar #3!
Webinar #3, on the topic of TIL Therapy Best Practices, will take place on Thursday, December 19, 2024. There will be 1.0 CE credits available for this third webinar, and the session will feature the following speakers:
- Andrea Fadel, BSN, RN, OCN, BMTCN
- Rebecca Gonzalez, PharmD, BCOP
- Eugene Przespolewski, PharmD, BCOP, DPLA
- Lauren Walford, RN, BSN, BMTCN
Watch here for more details!